You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 14, 2025

Salix Pharms Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Salix Pharms
International Patents:252
US Patents:28
Tradenames:9
Ingredients:8
NDAs:9

Drugs and US Patents for Salix Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 021361-002 Mar 24, 2010 RX Yes Yes 8,193,196 ⤷  Try for Free Y Y ⤷  Try for Free
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 021361-001 May 25, 2004 RX Yes Yes 10,703,763 ⤷  Try for Free ⤷  Try for Free
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 021361-002 Mar 24, 2010 RX Yes Yes 8,741,904 ⤷  Try for Free Y ⤷  Try for Free
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 021361-001 May 25, 2004 RX Yes Yes 7,928,115 ⤷  Try for Free ⤷  Try for Free
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-001 Apr 24, 2008 RX Yes Yes 8,822,490 ⤷  Try for Free Y ⤷  Try for Free
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 021361-002 Mar 24, 2010 RX Yes Yes 7,915,275 ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Salix Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Salix Pharms METOZOLV ODT metoclopramide hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 022246-001 Sep 4, 2009 6,413,549 ⤷  Try for Free
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-001 Apr 24, 2008 6,559,158 ⤷  Try for Free
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 021361-001 May 25, 2004 7,906,542 ⤷  Try for Free
Salix Pharms METOZOLV ODT metoclopramide hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 022246-002 Sep 4, 2009 6,413,549 ⤷  Try for Free
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 021361-001 May 25, 2004 7,045,620 ⤷  Try for Free
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 021361-001 May 25, 2004 8,158,781 ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for SALIX PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Orally Disintegrating Tablets 5 mg and 10 mg ➤ Subscribe 2010-08-24
➤ Subscribe Tablets 550 mg ➤ Subscribe 2015-12-18
➤ Subscribe Injection 12 mg/0.6 mL ➤ Subscribe 2015-07-22
➤ Subscribe Tablets 150 mg ➤ Subscribe 2016-09-06
➤ Subscribe Tablets 1.102 g and 0.398 g ➤ Subscribe 2008-04-09
➤ Subscribe Tablets 200 mg ➤ Subscribe 2019-01-28
➤ Subscribe For Oral Solution 100 g, 7.5 g, 2.691 g, 1.015 g, 5.9 g and 4.7 g per pouch ➤ Subscribe 2007-11-27
➤ Subscribe Injection 8 mg/0.4 mL ➤ Subscribe 2015-09-08

Supplementary Protection Certificates for Salix Pharms Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1856135 LUC00153 Luxembourg ⤷  Try for Free PRODUCT NAME: FOSTAMATINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE FOSTAMATINIB, OU UN HYDRATE, SOLVATE OU N-OXYDE DE FOSTAMATINIB OU LE SEL PHARMACEUTIQUEMENT ACCEPTABLE DE FOSTAMATINIB, EN PARTICULIER FOSTAMATINIB DISODIUM, EVENTUELLEMENT SOUS FORME D'HYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/19/1405 20200113
1758590 2017C/063 Belgium ⤷  Try for Free PRODUCT NAME: SEL DE SODIUM D'ACIDE DESOXYCHOLIQUE; AUTHORISATION NUMBER AND DATE: SE/H/1547/01/DC 20170612
0480717 98C0025 Belgium ⤷  Try for Free PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
3141251 301099 Netherlands ⤷  Try for Free PRODUCT NAME: A MEDICINAL PRODUCT CONSISTING OF A COMBINATION OF A FIRST DOSE PHARMACEUTICAL COMPOSITION AND A SECOND DOSE PHARMACEUTICAL COMPOSITION, THE FIRST DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, SODIUM SULPHATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE AND THE SECOND DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, ASCORBIC ACID, SODIUM ASCORBATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE; NATIONAL REGISTRATION NO/DATE: RVG 120195 20171114; FIRST REGISTRATION: IS IS/1/17/083/01 20171016
1507558 12C0033 France ⤷  Try for Free PRODUCT NAME: ALISKIRENE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE E CELUI-CI, AMLODIPINE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, ET HYDROCHLOROTHIAZIDE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/11/730/001 20111122; FIRST REGISTRATION: CH - 6167801 20110705
1507558 2012/018 Ireland ⤷  Try for Free PRODUCT NAME: ALISKIREN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AMLODIPINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; NAT REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION NO/DATE: SWITZERLAND 6167801-6167805 20110705
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: Salix Pharmaceuticals – Market Position, Strengths & Strategic Insights

Salix Pharmaceuticals, a subsidiary of Bausch Health, has established itself as a significant player in the pharmaceutical industry, particularly in the gastrointestinal (GI) therapeutics market. This comprehensive analysis delves into Salix's market position, strengths, and strategic insights, providing valuable information for industry professionals and investors alike.

Company Overview

Salix Pharmaceuticals, founded in 1989, has grown to become the largest gastroenterology-focused pharmaceutical company in the world[1]. Headquartered in Bridgewater, New Jersey, Salix specializes in developing and marketing prescription drugs and medical devices for various gastrointestinal disorders[1].

Market Position

Salix's strong market position is evident from its impressive financial performance and product portfolio. In 2014, the company reported total sales of $1.1 billion, showcasing its significant presence in the pharmaceutical industry[1].

Key Products

Salix's product lineup includes several successful treatments for GI disorders:

  1. XIFAXAN® 550: A leading product with 18% year-over-year prescription demand growth[2].
  2. APRISO®: Showed 10% year-over-year prescription demand growth[2].
  3. RELISTOR®: Experienced a remarkable 67% year-over-year prescription demand growth[2].
  4. UCERIS®: Demonstrated 47% year-over-year prescription demand growth[2].

These products have contributed significantly to Salix's market dominance in the GI therapeutics sector.

Financial Performance

Salix's financial performance underscores its strong market position:

  • Total net product revenue was projected to be between $1.25 billion and $1.35 billion in 2015[2].
  • Gross margins were estimated at approximately 80%[2].
  • EBITDA was projected to be between $360 million and $440 million[2].
"These important milestones should enhance our competitive position and expand our market opportunities," said Carolyn Logan, President and Chief Executive Officer of Salix Pharmaceuticals[7].

Strengths and Competitive Advantages

1. Focused Expertise

Salix's specialization in gastrointestinal disorders gives it a competitive edge in this niche market. This focused approach allows for deeper understanding and more targeted research and development efforts.

2. Strong Product Portfolio

The company's diverse range of GI treatments caters to various patient needs, solidifying its market position. Products like XIFAXAN® 550 and APRISO® have shown consistent growth, indicating their effectiveness and market acceptance[2].

3. Innovative Research and Development

Salix's commitment to innovation is evident from its strategic collaborations and research initiatives. The company has expanded its microbiome research and discovery through strategic partnerships, positioning itself at the forefront of GI treatment advancements[9].

4. Effective Acquisition Strategy

Salix has successfully grown through strategic acquisitions, such as InKine Pharmaceutical Company, Oceana Therapeutics, and Santarus[1]. These acquisitions have expanded its product portfolio and market reach.

Strategic Insights

1. Focus on Late-Stage and Marketed Products

Salix's strategy involves in-licensing or acquiring late-stage or marketed proprietary therapeutic products[8]. This approach minimizes development risks and accelerates time-to-market for new treatments.

2. Patent Protection

The company prioritizes patent protection for its key products. For instance, Apriso is expected to be patent-protected until 2022, ensuring continued revenue streams[8].

3. Diversification within GI Therapeutics

While maintaining its focus on GI disorders, Salix has diversified its product offerings to address various conditions within this therapeutic area. This strategy helps mitigate risks associated with over-reliance on a single product.

4. Strategic Partnerships

Salix actively pursues strategic partnerships to enhance its research capabilities and market reach. For example, its agreement with Photocure for Lumacan demonstrates its commitment to exploring new diagnostic technologies in GI care[1].

Competitive Landscape

In the GI therapeutics market, Salix faces competition from several pharmaceutical companies:

  1. AbbVie
  2. Boehringer Ingelheim
  3. Sucampo Pharmaceuticals (now part of Mallinckrodt)
  4. Ironwood Pharmaceuticals[5]

Despite this competition, Salix's focused approach and strong product portfolio have helped maintain its leading position in the GI therapeutics market.

Future Outlook

Salix's future looks promising, with several factors contributing to its potential growth:

  1. Expanding product pipeline
  2. Continued focus on GI disorders
  3. Strategic partnerships and collaborations
  4. Potential for international market expansion

However, the company also faces challenges, including:

  1. Intense competition in the pharmaceutical industry
  2. Regulatory hurdles
  3. Patent expirations of key products

Key Takeaways

  1. Salix Pharmaceuticals is the world's largest gastroenterology-focused pharmaceutical company.
  2. The company's strong product portfolio, including XIFAXAN® 550 and APRISO®, drives its market leadership.
  3. Salix's focused expertise in GI disorders provides a competitive advantage.
  4. Strategic acquisitions and partnerships have been crucial to Salix's growth and innovation.
  5. The company faces competition but maintains a strong position through its specialized approach and diverse product offerings.

FAQs

  1. Q: What is Salix Pharmaceuticals' primary focus? A: Salix Pharmaceuticals specializes in developing and marketing prescription drugs and medical devices for gastrointestinal disorders.

  2. Q: Who are Salix Pharmaceuticals' main competitors? A: Salix's main competitors include AbbVie, Boehringer Ingelheim, Sucampo Pharmaceuticals, and Ironwood Pharmaceuticals.

  3. Q: What are some of Salix Pharmaceuticals' key products? A: Some of Salix's key products include XIFAXAN® 550, APRISO®, RELISTOR®, and UCERIS®.

  4. Q: How does Salix Pharmaceuticals approach research and development? A: Salix focuses on in-licensing or acquiring late-stage or marketed proprietary therapeutic products and also engages in strategic partnerships for research and development.

  5. Q: What are the main challenges facing Salix Pharmaceuticals? A: The main challenges include intense competition in the pharmaceutical industry, regulatory hurdles, and the risk of patent expirations affecting its revenue base.

Sources cited: [1] https://en.wikipedia.org/wiki/Salix_Pharmaceuticals [2] https://www.fiercepharma.com/financials/salix-pharmaceuticals-provides-updates-on-wholesaler-inventory-reductions-and-xifaxan%C2%AE [5] https://pitchgrade.com/companies/ironwood-pharmaceuticals-inc [7] https://www.fiercepharma.com/financials/salix-pharmaceuticals-reports-3q2014-results [8] https://www.dcatvci.org/features/valeant-s-acquisition-of-salix-the-implications-in-specialty-pharma/ [9] https://ir.bauschhealth.com/~/media/Files/V/Valeant-IR/press-release/20180803-salix-expands-microbiome-research-and-discovery-through-strategic-collaboration.pdf

Last updated: 2025-02-13

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.